A false positive Alzheimer’s blood test can result from kidney dysfunction, age-related amyloid changes, another neurological condition, an unsuitable cutoff, or problems with the sample or assay. A false negative can occur when Alzheimer’s disease is still early, biomarker levels fall near the test’s threshold, the test measures a marker that is not strongly expressed in that person, or collection and handling reduce the measurable signal. For example, chronic kidney disease may raise blood levels of phosphorylated tau because the body clears the protein differently, potentially producing an Alzheimer’s-like result even when confirmatory testing does not show the disease. The meaning of “false” also requires care.
Most Alzheimer’s blood tests detect biological markers associated with amyloid or tau pathology; they do not independently establish that Alzheimer’s disease is causing someone’s memory problems. An older adult may have a positive amyloid-related result but remain cognitively healthy, while a person with worsening cognition may test negative because the actual cause is vascular dementia, Lewy body disease, depression, medication effects, or another condition. Results are most reliable when interpreted as part of a complete evaluation that includes symptoms, medical history, cognitive testing, physical and neurological examinations, and sometimes brain imaging or cerebrospinal fluid testing. The Alzheimer's Association emphasizes that no single test determines whether a person has Alzheimer’s disease or another dementia.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What Can Cause a False Positive Alzheimer’s Blood Test?
- Kidney Function, Other Illnesses, and Biological Confounders
- Why Can an Alzheimer’s Blood Test Be False Negative?
- How to Respond to a Positive, Negative, or Borderline Result
- Sample Handling, Assay Differences, and Cutoff Problems
- How Pretest Probability Changes the Meaning of the Result
- When Repeat or Confirmatory Testing Is Appropriate
- Frequently Asked Questions
What Can Cause a False Positive Alzheimer’s Blood Test?
A false positive occurs when a blood result crosses the laboratory’s positive threshold even though the reference test—usually amyloid positron emission tomography, or PET, or cerebrospinal fluid analysis—does not show corresponding Alzheimer’s pathology. Reduced kidney function is an important example. Several blood biomarkers, including phosphorylated tau forms such as p-tau181 and p-tau217, may accumulate when kidney clearance is impaired. Research has found that kidney dysfunction can raise these concentrations and complicate interpretation, particularly when a cutoff developed in people with healthier kidneys is applied without adjustment. Age and the population being tested also affect the chance that a positive result will be misleading.
Amyloid can accumulate in the brain years before dementia develops, and some cognitively healthy older people have amyloid-positive PET scans. Their blood test may accurately identify amyloid biology, yet it would be incorrect to conclude from that result alone that they have dementia or that Alzheimer’s explains an unrelated symptom such as temporary confusion during an infection. Some panels include neurofilament light, or NfL, and glial fibrillary acidic protein, or GFAP. These markers can reflect nerve-cell or astrocyte injury, but they are not exclusive to Alzheimer’s disease. Stroke, traumatic brain injury, multiple sclerosis, and other neurological disorders can affect them. Treating a nonspecific injury marker as proof of Alzheimer’s creates the same problem as treating a fever as proof of one particular infection.
Kidney Function, Other Illnesses, and Biological Confounders
Blood biomarker concentrations reflect what is happening throughout the body as well as in the brain. The kidneys help clear many proteins from circulation, so a reduced estimated glomerular filtration rate can elevate absolute concentrations of p-tau, NfL, and other markers. A study indexed by PubMed found that correcting p-tau results for renal function changed sensitivity and specificity, illustrating a tradeoff: an adjustment intended to prevent false positives may also cause some true cases to be missed. Other medical events can distort markers of neural injury. A recent stroke, head injury, seizure, or acute neurological illness may raise certain proteins without producing the Alzheimer’s-specific combination of amyloid and tau changes.
Liver disease, severe systemic illness, and altered blood composition may also matter for particular assays, although the size and direction of the effect depend on the biomarker and testing platform. Clinicians should avoid assuming that every health condition affects every Alzheimer’s marker in the same way. A warning is especially important when results are interpreted using a single cutoff. Someone just above the line may be labeled positive, while someone with an almost identical concentration just below it is labeled negative. Some laboratories use two thresholds—one for a likely negative result and another for a likely positive result—leaving an intermediate zone that requires additional evaluation. This reduces forced yes-or-no classifications but produces more inconclusive reports.
Why Can an Alzheimer’s Blood Test Be False Negative?
A false negative can occur when Alzheimer’s pathology is present but the measured biomarker has not risen or fallen enough to cross the test’s threshold. This is more likely during an early biological stage, when changes are subtle, or when the person’s value falls in the overlap between people with and without detectable brain amyloid. No biomarker has perfect separation across all patients. Different tests measure different targets. One may assess p-tau217, another p-tau181, and another the amyloid-beta 42-to-40 ratio. These markers do not change at exactly the same time or with identical magnitude.
For example, a person with early amyloid accumulation may have a borderline amyloid-related blood result before tau-related markers become clearly abnormal. A negative result from one assay therefore cannot automatically substitute for every other biomarker or reference method. Disease heterogeneity creates another limitation. People vary in genetics, coexisting brain disease, symptom pattern, and rate of progression. Alzheimer’s may also coexist with vascular damage or Lewy body disease. If Alzheimer’s contributes only part of the clinical picture, a weak or negative blood result can be incorrectly used to dismiss it, just as a positive result can be incorrectly used to ignore the coexisting disorder.
How to Respond to a Positive, Negative, or Borderline Result
The first practical step is to identify what the test actually measures and how the laboratory classifies the result. A p-tau217 concentration, an amyloid-beta ratio, and a combined biomarker score are not interchangeable. The report should be reviewed alongside kidney function, recent neurological events, medications and supplements, symptom history, and the reason testing was ordered. A positive triage test may require confirmation with amyloid PET or cerebrospinal fluid biomarkers. By comparison, a blood test is easier to obtain and less invasive, while PET can be costly and cerebrospinal fluid collection requires a lumbar puncture.
The tradeoff is that confirmatory methods provide a more direct assessment of Alzheimer’s-related brain pathology when a blood result is unexpected, borderline, or inconsistent with the clinical examination. A negative result also needs context. If a person has objective, progressive cognitive decline, clinicians should continue investigating other causes rather than declaring the evaluation finished. Brain imaging, cognitive assessment, laboratory testing for reversible contributors, sleep evaluation, and review of medications may reveal vascular disease, thyroid dysfunction, vitamin deficiency, sleep apnea, depression, or drug-related cognitive effects. Some of these conditions can coexist with Alzheimer’s rather than replace it.
Sample Handling, Assay Differences, and Cutoff Problems
The result can be affected before the sample reaches the analyzer. The type of collection tube, time before processing, temperature during transport, storage duration, repeated freezing and thawing, and contamination or breakdown of blood cells may alter measurements. The effect is not identical across biomarkers or platforms, so handling instructions supplied by the laboratory are part of the test—not an optional technical detail. Assays from different manufacturers may use different antibodies, calibration systems, units, calculations, and decision thresholds.
A value considered positive on one platform cannot necessarily be entered into the reference range for another. Switching laboratories during follow-up can create an apparent rise or fall that reflects the method rather than a biological change. Immunoassays can also be vulnerable to uncommon analytical interference from substances or antibodies in a patient’s blood. Certain supplements, including high-dose biotin, interfere with some laboratory methods, although this risk depends on the specific assay design. Patients should disclose supplements rather than stopping them without instructions, and an implausible result may warrant discussion with the laboratory or repeat testing on a fresh sample.
How Pretest Probability Changes the Meaning of the Result
Test performance depends partly on who is being tested. In a specialty memory clinic, where patients already have objectively verified cognitive impairment, a positive result is more likely to reflect clinically relevant Alzheimer’s pathology than the same result in a young person with no symptoms.
Testing very low-risk populations produces a larger proportion of false positives even when the assay’s sensitivity and specificity remain unchanged. For example, a positive result in a patient with steadily worsening episodic memory carries different weight from a positive result obtained through an unsupervised wellness screen in someone without cognitive concerns. Current Alzheimer's Association clinical guidance addresses blood biomarkers within the diagnostic workup of people with objective cognitive impairment in specialty care; it does not support treating indiscriminate population screening as equivalent.
When Repeat or Confirmatory Testing Is Appropriate
Repeat testing may be reasonable when the sample was mishandled, the result is near a cutoff, kidney function changed around the time of collection, or the finding sharply conflicts with the clinical picture. Repeating the same test immediately under unchanged conditions may reproduce the same uncertainty, so clinicians may instead use a properly collected new sample, a different validated biomarker, amyloid PET, or cerebrospinal fluid analysis.
A concrete example is a patient with severe renal impairment, a mildly elevated p-tau result, and a negative amyloid PET scan. The discrepancy should be documented and interpreted as possible renal confounding or assay-threshold uncertainty—not converted into an Alzheimer’s diagnosis on the blood value alone. Conversely, progressive memory loss with a negative blood test still warrants evaluation for non-Alzheimer’s dementias, structural brain disease, medication effects, and treatable medical contributors.
Frequently Asked Questions
Does a positive Alzheimer’s blood test mean a person has dementia?
No. A positive result may indicate Alzheimer’s-related amyloid or tau biology, but dementia is a clinical condition involving cognitive decline that interferes with daily function. Symptoms, examination findings, cognitive testing, and other diagnostic information are needed.
Can kidney disease cause a positive p-tau result?
Reduced kidney function can raise circulating p-tau concentrations and increase the possibility of a misleading positive result. The degree of concern depends on the assay, kidney impairment, cutoff, and other clinical evidence.
Can someone have Alzheimer’s disease despite a negative blood test?
Yes. Early or borderline pathology, biological variation, assay limitations, and sample problems can produce false negatives. Alzheimer’s can also coexist with another disorder even when the measured marker is not clearly positive.
Should an abnormal blood test be repeated?
Repeat testing may help when collection or processing was questionable, the result is borderline, or an acute illness may have affected it. A different biomarker, amyloid PET, or cerebrospinal fluid test may be more informative than simply repeating the same assay.
Are all Alzheimer’s blood tests equivalent?
No. Tests may measure different forms of phosphorylated tau, amyloid-beta ratios, or combined scores, and each platform has its own calibration and cutoffs. Results from different assays should not be compared as if they used a common scale.
